Sanofi: Dupixent approved for asthma in US
(CercleFinance.com) - Sanofi announces that the US FDA has approved Dupixent (dupilumab) an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
The French health giant states that in clinical trials, Dupixent helped to reduce severe asthma exacerbations and oral corticosteroids, and to improve patients' respiratory capacity.
George D. Yancopoulos, President and Chief Scientific Officer of Regeneron said that this drug is now approved in the treatment of atopic dermatitis and asthma and that the group has recently announced positive phase III results in chronic rhinosinusitis with nasal polyps.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The French health giant states that in clinical trials, Dupixent helped to reduce severe asthma exacerbations and oral corticosteroids, and to improve patients' respiratory capacity.
George D. Yancopoulos, President and Chief Scientific Officer of Regeneron said that this drug is now approved in the treatment of atopic dermatitis and asthma and that the group has recently announced positive phase III results in chronic rhinosinusitis with nasal polyps.
Copyright (c) 2018 CercleFinance.com. All rights reserved.